Article

Annovis Bio Announces First Patient Dosed in Phase 3 Trial in Patients with Early Parkinson’s Disease

09/02/2022

Excerpt from the Press Release: BERWYN, Pa., Aug. 24, 2022 /PRNewswire/ — Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company addressing neurodegenerative diseases, announced today that the first patient in the Phase 3 clinical trial evaluating buntanetap in early Parkinson’s Disease (PD) has been dosed. The Phase 3 trial…

Read More

Sight Sciences Introduces the SION™ Surgical Instrument – The First Bladeless Device Used in Goniotomy

09/01/2022

Featuring bladeless technology, SION is designed to facilitate a smooth, gentle goniotomy procedure Excerpt from the Press Release: MENLO PARK, Calif., Aug. 23, 2022 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing and commercializing innovative solutions intended to transform care and improve patients’ lives, today announced the launch…

Read More

Imperative Care Announces Positive New Data Underscoring the Safety and Efficacy of the Zoom Stroke Solution to Treat Distal Occlusions in Ischemic Stroke Patients

09/01/2022

Independent Data Presented at the World Federation of Interventional and Therapeutic Neuroradiology 2022 Annual Meeting Highlights the Benefits of Vessel-Matching with Zoom Reperfusion Catheters Excerpt from the Press Release: CAMPBELL, Calif.–(BUSINESS WIRE)–Imperative Care, Inc. today announced that new data evaluating the utility of the Zoom Stroke Solution were presented at the World Federation of Interventional…

Read More

Study Published in JHEP Reports Shows Efruxifermin Rapidly Improved Fibrosis in Cirrhotic NASH patients After 16 Weeks of Treatment

08/31/2022

33% improved by one fibrosis stage without worsening of NASH; 25% of patients treated with efruxifermin showed NASH resolution Consistent with the results for the pre-cirrhotic population (F1-F3), patients with cirrhosis also had improved markers of liver injury, glucose metabolism, and lipid metabolism Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Aug. 24, 2022…

Read More

Stoke Therapeutics Enrolls First Patient in a Natural History Study of People Living with Autosomal Dominant Optic Atrophy (ADOA)

08/31/2022

– ADOA is primarily caused by mutations in the OPA1 gene that result in progressive and irreversible vision loss in both eyes starting in the first decade of life – – The FALCON study is designed to evaluate disease progression and its effects on patients – – Data will support clinical development plans for STK-002,…

Read More

UBC researchers say they’ve found ‘weak spot’ in all COVID-19 variants that could lead to better treatment

08/29/2022

Scientists say certain antibody fragment effectively neutralized variants by latching to vulnerability Excerpt from the Press Release: Researchers at the University of British Columbia (UBC) have discovered what they describe as a “weak spot” in all of the major variants of the virus that causes COVID-19 — a revelation they believe could open the door for treatments to fight current…

Read More

Sight Sciences Announces Long-Term Safety and Effectiveness Data of Standalone Use of the OMNI® Surgical System in Patients with Open Angle Glaucoma

08/29/2022

Three-year, standalone (not combined with cataract surgery) data shows the non-implantable minimally invasive glaucoma surgery effectively reduces intraocular pressure and reduces need for IOP-lowering medications in open-angle glaucoma patients Excerpt from the Press Release: MENLO PARK, Calif., Aug. 16, 2022 (GLOBE NEWSWIRE) — Sight Sciences, Inc. (Nasdaq: SGHT), an eyecare technology company focused on developing…

Read More

CureVac Starts Phase 1 Clinical Study of Modified, Omicron-Targeting COVID-19 Vaccine Candidate

08/26/2022

Phase 1 dose-escalation study to be conducted at clinical sites in the U.S., the UK, Australia, and the Philippines Milestone demonstrates CureVac’s continued execution on comprehensive clinical program of second-generation vaccine candidates for infectious diseases Excerpt from the Press Release: TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 18, 2022 / CureVac N.V. (Nasdaq:CVAC),…

Read More

Cellarity Releases Novel, Open-Source, Single-Cell Dataset and Invites the Machine Learning and Computational Biology Communities to Develop New Algorithms Capable of Learning Fundamental Rules of Cell Behavio

08/26/2022

The dataset will be publicly available for a Kaggle competition presented at NeurIPS 2022 hosted by Open Problems in Single-Cell Analysis in collaboration with Chan Zuckerberg Initiative, Chan Zuckerberg Biohub, Yale University, and Helmholtz Munich Excerpt from the Press Release: SOMERVILLE, Mass.–(BUSINESS WIRE)–Cellarity, a life sciences company founded by Flagship Pioneering to transform the way…

Read More

SpIntellx and iCura Diagnostics Partner to Expand Access to Advanced Spatial Analytics and Explainable AI Products for Pathology and Oncology Research

08/23/2022

SpIntellx, Inc., a leader in spatially intelligent biology, and iCura Diagnostics, a leading contract research organization (CRO) focused on capitalizing multiomic data to accelerate end-to-end clinical workflow solutions and biomarker discovery, today announced a partnership to transform precision oncology through unlocking the power of genomic, proteomics, and transcriptomic data using advanced spatial analytics. Excerpt from…

Read More